New €210M Life Sciences Fund is Launched in UK

02/02/2016 - 2 minutes

Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a €210M Fund including GSK and Johnson & Johnson Innovation.

medicxi_ventures_index_vc_biotech_life_sciencesMedicxi Ventures is based in London, Geneva and Jersey and has been investing in the Life Sciences field for over 20 years.

It comprises all of the legacy portfolio companies, funds and the life sciences team of Index Ventures, and a new €210 million fund (MV1) that will focus on early-stage investments in life sciences.

The Company’s mission is to invest and collaborate predominantly in Europe along the full healthcare continuum (Biotech and Academia), with a focus on drug discovery and development.


MV1 will focus on early-stage life sciences investments in Europe in a similar approach to that pioneered by its partners at Index.

By investing in MV1, GSK and Johnson & Johnson Innovation (JJDC) have renewed and expanded their commitment to the asset-centric approach,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!